BSE Live
Jan 29, 16:01Prev. Close
2433.55
Open Price
2495.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 29, 15:59Prev. Close
2434.20
Open Price
2438.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2366.60 (462)
| Key Financial Ratios of GlaxoSmithKline Pharmaceuticals (in Rs. Cr.) | Dec 04 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 38.15 | |
| Diluted EPS (Rs.) | 38.15 | |
| Cash EPS (Rs.) | 40.15 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 105.84 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 105.84 | |
| Dividend / Share(Rs.) | 24.00 | |
| Revenue from Operations/Share (Rs.) | 156.63 | |
| PBDIT/Share (Rs.) | 46.89 | |
| PBIT/Share (Rs.) | 44.89 | |
| PBT/Share (Rs.) | 44.68 | |
| Net Profit/Share (Rs.) | 38.15 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 29.93 | |
| PBIT Margin (%) | 28.66 | |
| PBT Margin (%) | 28.52 | |
| Net Profit Margin (%) | 24.35 | |
| Return on Networth / Equity (%) | 36.03 | |
| Return on Capital Employed (%) | 35.31 | |
| Return on Assets (%) | 23.57 | |
| Total Debt/Equity (X) | 0.00 | |
| Asset Turnover Ratio (%) | 96.80 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 1.03 | |
| Quick Ratio (X) | 0.55 | |
| Inventory Turnover Ratio (X) | 6.04 | |
| Dividend Payout Ratio (NP) (%) | 62.91 | |
| Dividend Payout Ratio (CP) (%) | 59.78 | |
| Earnings Retention Ratio (%) | 37.09 | |
| Cash Earnings Retention Ratio (%) | 40.22 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 6,658.62 | |
| EV/Net Operating Revenue (X) | 4.87 | |
| EV/EBITDA (X) | 16.26 | |
| MarketCap/Net Operating Revenue (X) | 4.91 | |
| Retention Ratios (%) | 37.08 | |
| Price/BV (X) | 7.27 | |
| Price/Net Operating Revenue | 4.91 | |
| Earnings Yield | 0.05 |
12.11.2025
GlaxoSmithKline Standalone September 2025 Net Sales at Rs 973.63 crore, down 2.64% Y-o-Y
07.11.2025
GlaxoSmithKline Consolidated September 2025 Net Sales at Rs 979.94 crore, down 3.05% Y-o-Y
12.08.2025
GlaxoSmithKline Consolidated June 2025 Net Sales at Rs 805.17 crore, down 1.16% Y-o-Y
01.08.2025
GlaxoSmithKline Standalone June 2025 Net Sales at Rs 804.83 crore, down 0.76% Y-o-Y